
Opinion|Videos|August 1, 2024
Unmet Needs in IPF Landscape
Author(s)Justin Oldham, MD, MS
Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the current unmet needs in IPF treatment and why is it necessary to develop new pharmacotherapies for this disease?
- What biomarkers are currently used for the diagnosis of IPF?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic
3
Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5



